Browse by category

The FDA has approved Eli Lilly and Company’s Foundayo (orforglipron) for adults with obesity or overweight with weight-related medical problems.  Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist (GLP-1ra) that can be taken any time of the day without restrictions on food and water intake. "People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with n

Olympus Corporation has launched the VISERA ELITE III surgical imaging platform designed to enhance surgical visualization, workflow efficiency and multispecialty flexibility, in the US. The VISERA ELITE III platform is a significant leap forward in surgical imaging and the third major co-developed product by SONY Olympus Medical (SOMED), a joint venture established in 2013. The VISERA ELITE III surgical imaging platform offers advanced features including Yellow Enhancement (

The FDA has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System (AGBS), featuring the Allurion Smart Capsule. The Allurion Program is a weight-loss platform that combines the FDA PMA approved Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, with the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers featuring the Iris AI platform, Allurion Insights for healthcare providers, and the Allurion

The European Commission has granted final approval of a higher 7.2 mg maintenance dose of Wegovy (semaglutide) for adults who may need extra help losing weight. It is now approved in all 27 countries in the European Union. This gives doctors another option to help adults who need more weight loss after being on the 2.4 mg dose. The approval is based on a positive opinion from the European Medicines Agency’s scientific committee (CHMP) on 12 December 2025. The approval means t

The FDA has approved Novo Nordisk’s once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the US. The Wegovy pill can be used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off. The pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with

Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2

The first patient has been treated in Nitinotes’ US Investigational Device Exemption (IDE) EASE Clinical Trial evaluating the EndoZip Automated Suturing System for endoscopic sleeve gastroplasty (ESG). The procedure was performed at Lenox Hill Hospital | Northwell Health in New York, NY, the trial's first activated US site. The EASE Clinical Trial is a prospective, multi-centre, randomised, two-arm, blinded pivotal study designed to evaluate the safety and effectiveness of th

Transoral outlet reduction (TORe) and anastomotic reduction techniques are gaining momentum as minimally invasive alternatives to surgical revision for managing post-surgical complications such as weight regain and dumping syndrome.(1) BARS® — a novel endoscopic platform developed by Ovesco Endoscopy AG — is among the emerging technologies in this field. As clinical experience with BARS® grows, early data on weight regain management and targeted treatment approaches for enlar

Just a few months after the world’s first gastric mucosal ablation (GMA) case using MOVIVA (Erbe Elektromedizin) at the Policlinico Universitario Agostino Gemelli in Rome, clinical experience is rapidly expanding across Europe. With around 80 procedures performed within a short timeframe in eight countries, MOVIVA is helping to establish a new era of endoscopic bariatric treatment – offering a less invasive option as obesity rates continue to rise worldwide. Gastric mucosal a

Novo Nordisk announced the submission of a sNDA to the FDA for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity. Under the CNPV expedited program, review is expected within 1–2 months following the FDA's acceptance of the filing. The sNDA includes results from STEP UP, a 72-week phase 3, randomised, double-blind, placebo-controlled and active-control